Your browser doesn't support javascript.
loading
Effects of Add-On Ultramicronized N-Palmitol Ethanol Amide in Patients Suffering of Migraine With Aura: A Pilot Study.
Chirchiglia, Domenico; Cione, Erika; Caroleo, Maria C; Wang, Minyan; Di Mizio, Giulio; Faedda, Noemi; Giacolini, Teodosio; Siviglia, Serena; Guidetti, Vincenzo; Gallelli, Luca.
Afiliação
  • Chirchiglia D; Department of Medical and Surgical Science, School of Medicine, University of Catanzaro, Catanzaro, Italy.
  • Cione E; Department of Pharmacy Health and Nutritional Sciences, University of Calabria, Rende, Italy.
  • Caroleo MC; Department of Pharmacy Health and Nutritional Sciences, University of Calabria, Rende, Italy.
  • Wang M; Department of Biological Sciences, Centre for Neuroscience, Xi'an Jiaotong-Liverpool University, Suzhou, China.
  • Di Mizio G; Department of Law, Ecenomy and Sociology, University of Catanzaro, Catanzaro, Italy.
  • Faedda N; Section of Child and Adolescent Neuropsychiatry, Department of Human Neuroscience, "Sapienza" University, Rome, Italy.
  • Giacolini T; Section of Child and Adolescent Neuropsychiatry, Department of Human Neuroscience, "Sapienza" University, Rome, Italy.
  • Siviglia S; Clinical Pharmacology and Pharmacovigilance Operative Unit, Department of Health Science, University of Catanzaro, Mater Domini Hospital Catanzaro, Catanzaro, Italy.
  • Guidetti V; Section of Child and Adolescent Neuropsychiatry, Department of Human Neuroscience, "Sapienza" University, Rome, Italy.
  • Gallelli L; Clinical Pharmacology and Pharmacovigilance Operative Unit, Department of Health Science, University of Catanzaro, Mater Domini Hospital Catanzaro, Catanzaro, Italy.
Front Neurol ; 9: 674, 2018.
Article em En | MEDLINE | ID: mdl-30177906
Background: Palmitoyl ethanol amide (PEA) is an endogenously produced substance showing anti-nociceptive effect through both receptor and non-receptor mediated effects at the level of different cellular and tissue sites. This study showed the results of a single blind study that was conducted to evaluate both the safety and the efficacy of ultramicronized PEA (umPEA; 1,200 mg/day) for up 90 days in patients suffering of Migraine with Aura (MA) treated with NSAIDs. Methods: A total of 20 patients, 8 male (33-56-years, average 41.4 ± 7.8) and 12 female (19-61-years, average 38.5 ± 11.9) with MA were admitted to our observation and diagnosed according to ICHD-3 criteria, they received umPEA (1,200 mg/day) in combination with NSAIDs for up to 90 days. They were revaluated at 30, 60, and 90 days after treatment. Results: umPEA administration induced a statistically significant and time dependent pain relief. In particular, these effects were evident at 60 days (male P = 0.01189; female P = <0.01) and they lasted until the end of the study (male P = 0.0066; female P = 0.01473). Conclusion: Although further studies are needed, our findings indicate that in patients suffering of MA treatment with umPEA had good efficacy and safety which candidate this compound as a therapeutic tool in pain migraine management.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Front Neurol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Front Neurol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália